scopolamine butylbromide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
458 7182-53-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buscopan
  • scopolamine butyl hydroxide
  • scopolamine butylbromide
  • hyoscine butylbromide
  • butylscopolamine
  • butylscopolammonium
  • butylscopolamine bromide
  • n-butylscopolammonium
  • n-butylscopolammonium bromide
Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.
  • Molecular weight: 360.47
  • Formula: C21H30NO4
  • CLOGP: -1.09
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 59.06
  • ALOGS: -5.29
  • ROTB: 8

Drug dosage:

DoseUnitRoute
60 mg O
60 mg P
60 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.69 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1951 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 147.11 15.78 195 8926 293261 63186640
Constipation 63.67 15.78 115 9006 224828 63255073
Swelling face 53.07 15.78 55 9066 63420 63416481
Swollen tongue 50.35 15.78 41 9080 34759 63445142
Angioedema 46.41 15.78 45 9076 47920 63431981
Lymphoedema 44.22 15.78 25 9096 11667 63468234
Hydronephrosis 43.60 15.78 24 9097 10638 63469263
Dysphonia 34.05 15.78 38 9083 47576 63432325
Aphonia 34.01 15.78 20 9101 10043 63469858
Vomiting 33.70 15.78 164 8957 559453 62920448
Diarrhoea 31.21 15.78 192 8929 715174 62764727
Infective exacerbation of chronic obstructive airways disease 30.33 15.78 10 9111 1247 63478654
Lip swelling 29.77 15.78 29 9092 31034 63448867
Naevus haemorrhage 28.61 15.78 6 9115 125 63479776
Colitis ulcerative 28.13 15.78 26 9095 26065 63453836
Acarodermatitis 27.68 15.78 9 9112 1074 63478827
Drug ineffective for unapproved indication 27.53 15.78 29 9092 34034 63445867
Obstructive pancreatitis 26.29 15.78 7 9114 416 63479485
Purulent discharge 26.12 15.78 13 9108 4693 63475208
Chemical burns of eye 24.80 15.78 5 9116 85 63479816
Adrenocortical insufficiency acute 23.72 15.78 9 9112 1689 63478212
Essential tremor 23.64 15.78 8 9113 1080 63478821
Colitis 22.26 15.78 31 9090 48497 63431404
Arthropod bite 22.19 15.78 14 9107 7964 63471937
Bowel movement irregularity 21.94 15.78 12 9109 5252 63474649
Metastatic gastric cancer 21.63 15.78 5 9116 165 63479736
Skin warm 21.49 15.78 12 9109 5464 63474437
Hepatitis E 21.43 15.78 8 9113 1436 63478465
Arthropathy 21.25 15.78 4 9117 234788 63245113
Subcutaneous abscess 21.25 15.78 12 9109 5584 63474317
Urinary tract infection 19.93 15.78 83 9038 264601 63215300
Enterocolitis 19.91 15.78 13 9108 7845 63472056
Perforation 19.20 15.78 7 9114 1176 63478725
Systemic lupus erythematosus 17.99 15.78 4 9117 208914 63270987
Intestinal obstruction 17.67 15.78 22 9099 30877 63449024
Malaise 17.64 15.78 111 9010 415843 63064058
Encephalopathy neonatal 17.57 15.78 3 9118 19 63479882
Oligohydramnios 17.28 15.78 11 9110 6355 63473546
Pharyngeal swelling 17.22 15.78 11 9110 6393 63473508
Contraindicated product administered 17.14 15.78 5 9116 217643 63262258
Off label use 16.86 15.78 159 8962 674303 62805598
Drug diversion 16.85 15.78 6 9115 942 63478959
Product substitution error 16.74 15.78 3 9118 26 63479875
Glossodynia 16.28 15.78 3 9118 178873 63301028
Anal skin tags 16.07 15.78 5 9116 518 63479383
Pancreatitis haemorrhagic 15.97 15.78 5 9116 528 63479373
Vulvovaginal swelling 15.81 15.78 5 9116 546 63479355

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 54.85 20.21 77 3675 163541 34789638
Pancreatic neoplasm 41.10 20.21 11 3741 897 34952282
Genitalia external ambiguous 38.25 20.21 8 3744 223 34952956
Congenital bladder anomaly 36.63 20.21 8 3744 275 34952904
Foetal hypokinesia 34.20 20.21 8 3744 376 34952803
Neonatal respiratory depression 33.39 20.21 8 3744 417 34952762
Anomaly of external ear congenital 31.08 20.21 6 3746 110 34953069
Vomiting 30.76 20.21 76 3676 247545 34705634
External auditory canal atresia 28.23 20.21 6 3746 181 34952998
Foetal exposure during pregnancy 28.12 20.21 27 3725 38074 34915105
Lung adenocarcinoma 26.62 20.21 12 3740 4659 34948520
Hypomagnesaemia 25.25 20.21 20 3732 21831 34931348
Tumour invasion 25.17 20.21 6 3746 306 34952873
Decubitus ulcer 24.54 20.21 14 3738 8907 34944272
Diarrhoea 22.66 20.21 92 3660 389820 34563359
Intercepted product storage error 21.60 20.21 5 3747 224 34952955
Atrial septal defect 21.41 20.21 12 3740 7380 34945799

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abdominal pain 176.91 14.93 253 11763 389316 79343056
Constipation 71.86 14.93 142 11874 282908 79449464
Swollen tongue 61.23 14.93 51 11965 42519 79689853
Diarrhoea 54.59 14.93 269 11747 880220 78852152
Vomiting 51.31 14.93 217 11799 665611 79066761
Swelling face 49.01 14.93 57 11959 71155 79661217
Lymphoedema 34.12 14.93 22 11994 12391 79719981
Malaise 33.34 14.93 154 11862 489715 79242657
Aphonia 32.67 14.93 20 11996 10292 79722080
Pancreatic neoplasm 32.14 14.93 11 12005 1465 79730907
Dysphonia 31.79 14.93 41 11975 56831 79675541
Hydronephrosis 31.72 14.93 24 11992 17430 79714942
Enterocolitis 30.99 14.93 22 11994 14490 79717882
Naevus haemorrhage 28.32 14.93 6 12010 125 79732247
Angioedema 28.07 14.93 45 11971 75990 79656382
Colitis 27.91 14.93 44 11972 73263 79659109
Intestinal obstruction 27.22 14.93 33 11983 42987 79689385
Lip swelling 26.89 14.93 32 11984 40879 79691493
Acarodermatitis 25.01 14.93 9 12007 1389 79730983
Urinary tract infection 23.82 14.93 93 11923 274419 79457953
Chemical burns of eye 23.01 14.93 5 12011 118 79732254
Levator syndrome 22.65 14.93 4 12012 30 79732342
Purulent discharge 22.49 14.93 13 12003 6026 79726346
Infective exacerbation of chronic obstructive airways disease 22.14 14.93 10 12006 2774 79729598
Metastatic gastric cancer 22.10 14.93 6 12010 366 79732006
Tumour invasion 21.67 14.93 6 12010 394 79731978
Colitis ulcerative 20.92 14.93 26 11990 34716 79697656
Arthropod bite 20.81 14.93 14 12002 8457 79723915
Lower respiratory tract infection 20.60 14.93 54 11962 129166 79603206
Essential tremor 20.48 14.93 8 12008 1547 79730825
Abdominal pain upper 20.37 14.93 77 11939 223742 79508630
Intercepted product storage error 19.23 14.93 5 12011 258 79732114
Nephrolithiasis 18.93 14.93 31 11985 53260 79679112
Skin warm 18.83 14.93 12 12004 6620 79725752
Nausea 18.67 14.93 223 11793 956973 78775399
Perforation 17.60 14.93 7 12009 1419 79730953
Pharyngeal swelling 17.17 14.93 12 12004 7707 79724665
Arthropathy 17.15 14.93 3 12013 177108 79555264
Lung adenocarcinoma 16.97 14.93 12 12004 7852 79724520
Vulvovaginal swelling 16.97 14.93 5 12011 410 79731962
Decubitus ulcer 16.97 14.93 16 12000 15671 79716701
Subcutaneous abscess 16.86 14.93 12 12004 7937 79724435
Metastases to oesophagus 16.04 14.93 3 12013 32 79732340
Myocardial infarction 16.02 14.93 4 12012 184125 79548247
Administration site swelling 15.91 14.93 5 12011 510 79731862
Adrenocortical insufficiency acute 15.33 14.93 8 12008 3035 79729337
Hepatitis alcoholic 15.00 14.93 5 12011 615 79731757
Skin infection 14.94 14.93 16 12000 18229 79714143

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03BB01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
BELLADONNA AND DERIVATIVES, PLAIN
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
ATC A03DB04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
ANTISPASMODICS IN COMBINATION WITH ANALGESICS
Belladonna and derivatives in combination with analgesics
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:53784 antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Gastric spasm indication 196754001




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Horses Abdominal pain (colic) associated with spasmodic colic Indication
Horses Flatulent colic Indication
Horses Simple impactions Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Buscopan Injectable Solution Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR WOMBAT-PK

External reference:

IDSource
149-64-4 SECONDARY_CAS_RN
1085787 RXNORM
C0006519 UMLSCUI
CHEBI:32123 CHEBI
CHEMBL1256901 ChEMBL_ID
6852391 PUBCHEM_CID
CHEMBL1618102 ChEMBL_ID
DB09300 DRUGBANK_ID
1156229000 SNOMEDCT_US
395739004 SNOMEDCT_US
D002086 MESH_DESCRIPTOR_UI
2Z3E1OF81V UNII
003459 NDDF

Pharmaceutical products:

None